Alzinova to participate in several international industry and investor events during spring and summer 2026

Following the completed rights issue and continued preparations for the planned Phase II study with the vaccine candidate ALZ-101, Alzinova is intensifying its international presence in forums where leading stakeholders in neurodegenerative diseases, life science investment and drug development meet.

By participating in these events, the company will have the opportunity to present the clinical and regulatory progress made in the development of ALZ-101, while also deepening discussions with potential partners and investors. Several of the conferences represent key global meeting points for pharmaceutical companies, researchers and capital market participants focusing on neurological diseases and disease-modifying therapies.

Alzinova plans to participate in the following events during 2026:

Carnegie Healthcare Micro Cap Event – Digital, March 9, 2026
A digital investor event focused on companies within the healthcare sector where Alzinova will present the company’s strategy and the development of ALZ-101.

AD/PD Conference – Copenhagen, Denmark, March 17–21, 2026
One of the world’s leading scientific conferences on Alzheimer’s and Parkinson’s disease, bringing together researchers, clinicians and pharmaceutical companies to discuss the latest developments in neurodegenerative diseases.

BIO-Europe Spring – Lisbon, Portugal, March 23–25, 2026
One of Europe’s most important life science partnering conferences, where the company will meet international pharmaceutical companies, investors and potential collaboration partners.

Redeye Theme: Alzheimer’s – Stockholm, Sweden, April 9, 2026
A thematic event hosted by Redeye focusing on companies active in the Alzheimer’s field and the latest developments in disease-modifying treatments.

BIO International Convention – San Diego, USA, June 22–25, 2026
One of the world’s largest life science partnering conferences where global pharmaceutical companies, investors and biotechnology companies meet to explore collaborations and future development opportunities.

Alzheimer’s Association International Conference (AAIC) – London, United Kingdom, July 12–15, 2026
The largest global conference on Alzheimer’s research where leading scientists and industry representatives present new scientific and clinical advances in the field.

Together, these conferences represent important platforms for increasing the international visibility of Alzinova’s vaccine strategy and for advancing discussions around the next development steps for ALZ-101.

A complete and updated overview of Alzinova’s planned events is available on the company’s website:
https://www.alzinova.com/upcoming-events/

For further information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com

About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 55 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com